Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 16,122 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Completed Phase 1 Interventional

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT03050151
View directory record Official record
Conditions
Atopic Disorders, Eczema, Atopic
Interventions
Dupilumab, Auto-injector Device, Prefilled syringe
Drug · Device
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 30, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus

NCT00730002
View directory record Official record
Conditions
Neuropsychiatric Systemic Lupus Erythematosus
Interventions
Magnetic Resonance Angiography (MRA), Magnetic resonance imaging, MRA, diffusion Imaging, perfusion imaging.
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 30, 2026, 5:51 PM EDT
Not listed No phase listed Observational

A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients

NCT04699695
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Biologic therapy versus no biologic therapy
Other
Lead sponsor
DermTech
Other
Eligibility
1 Year and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 30, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

A Study of Different Use Regimens Using Two Acne Treatments

NCT00907257
View directory record Official record
Conditions
Acne Vulgaris
Interventions
benzoyl peroxide wash, Tretinoin gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Boca Raton, Florida • Miami, Florida • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 30, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

Safety Study of Multikine in the Treatment of Perianal Warts

NCT02115919
View directory record Official record
Conditions
Condyloma
Interventions
Leukocyte Interleukin, Injection 200IU, Leukocyte Interleukin, injection 400IU
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 30, 2026, 5:51 PM EDT
Terminated No phase listed Observational

Measuring the Effect of Radiation Therapy on Patient Activity Levels

NCT02694380
View directory record Official record
Conditions
Head and Neck Cancer, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 30, 2026, 5:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection and Distribution of Biospecimens for Novel Research Uses

NCT03848962
View directory record Official record
Conditions
Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases, Infectious Disease, Women's Health: High-Risk Pregnancy, Dermatologic Disease, Blood Disease
Interventions
Not listed
Lead sponsor
iSpecimen Inc
Industry
Eligibility
1 Month to 89 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Huntsville, Alabama • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 30, 2026, 5:51 PM EDT
Withdrawn Phase 2 Interventional

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

NCT01355562
View directory record Official record
Conditions
Melanoma, Metastatic Kidney Cancer
Interventions
Interleukin-2 (IL-2)
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Beaumont, California • Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 30, 2026, 5:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

NCT00669942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Anniston, Alabama • Tucson, Arizona • Largo, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 30, 2026, 5:51 PM EDT
Recruiting Not applicable Interventional

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

NCT06939686
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
Interventions
Miro3D Wound Matrix, Standard of Care (SOC)
Device · Other
Lead sponsor
Reprise Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Coconut Creek, Florida • Tamarac, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 30, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

NCT01547741
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
914
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 5:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Two Heel Protection Devices to Assess Off-loading Via Pressure Mapping.

NCT07734220
View directory record Official record
Conditions
Pressure Injuries
Interventions
HeelMedix Basic & EHOB Waffle
Device
Lead sponsor
Medline Industries
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Northfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 30, 2026, 5:51 PM EDT
Withdrawn Phase 1 Interventional

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

NCT03617224
View directory record Official record
Conditions
Cutaneous T-Cell Lymphomas
Interventions
TSEBT, TSEBT and pembrolizumab
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 30, 2026, 5:51 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries

NCT05496296
View directory record Official record
Conditions
Pressure Ulcers Stage II, Pressure Ulcers Stage III, Pressure Ulcer, Stage IV
Interventions
Altrazeal® Transforming Powder Dressing
Device
Lead sponsor
ULURU Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 30, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison Study of Topical Acne Regimens

NCT00913185
View directory record Official record
Conditions
Acne
Interventions
Acne Free, Proactiv
Drug
Lead sponsor
MedDerm Associates
Industry
Eligibility
13 Years to 45 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 30, 2026, 5:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis

NCT01105715
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 30, 2026, 5:51 PM EDT
Completed Not applicable Interventional

Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors

NCT02662335
View directory record Official record
Conditions
Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Computer-Assisted Cognitive Training, Questionnaire Administration, Standard Follow-Up Care
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 30, 2026, 5:51 PM EDT
Terminated No phase listed Observational

Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer

NCT04088435
View directory record Official record
Conditions
Breast Cancer, Breast Cancer, Invasive Ductal, Invasive Mammary Carcinoma, Breast Cancer Stage I, Breast Cancer Stage IIA
Interventions
Intraoperative radiotherapy
Radiation
Lead sponsor
University of Louisville
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 30, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

NCT03905525
View directory record Official record
Conditions
Sjögren Syndrome
Interventions
CFZ533, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 5:51 PM EDT
Withdrawn Not applicable Interventional

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

NCT02507076
View directory record Official record
Conditions
Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage III Adult Soft Tissue Sarcoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Melanoma
Interventions
isolated limb perfusion, melphalan, quality-of-life assessment
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 30, 2026, 5:51 PM EDT
Completed No phase listed Observational

Collecting Solid Tumor Tissue to Identify New Treatments

NCT01658917
View directory record Official record
Conditions
Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 30, 2026, 5:51 PM EDT
Not yet recruiting No phase listed Observational

Together-Breast Cancer Support Platform

NCT07499089
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Survivors
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 30, 2026, 5:51 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

NCT00657189
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus
Interventions
MEDI-545, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
22
States / cities
Anniston, Alabama • Huntington Beach, California • Upland, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 30, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

NCT02339324
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab and high dose interferon alfa-2b (HDI)
Drug
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Buffalo, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 30, 2026, 5:51 PM EDT